Ronald Fischer, a fugitive who evaded scrutiny for two decades, was caught using an alias in the biotech industry, according to STAT.[6179739] The FDA has raised concerns that Capricor Therapeutics' stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial, contrary to company claims last year.[6153138][6016659][6019994] GSK CEO Luke Miels has outlined plans to cut costs and pursue more late-stage drug trials as part of his efforts to turn the UK pharma giant into a more agile company.[6023335] The FDA staff have reiterated concerns that Replimune's skin cancer treatment does not have adequate data to support an approval, as the biotech tries for the third time to seek clearance.[6019994]